203 related articles for article (PubMed ID: 27345657)
41. [Significance of HPV and cell cycle related proteins in basaloid squamous cell carcinoma of the larynx].
Cui LF; Chang H; Zhao HY; Qu CL; Gao Y; Liu HG
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):682-686. PubMed ID: 30220121
[No Abstract] [Full Text] [Related]
42. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma.
Gleber-Netto FO; Neskey D; Costa AFM; Kataria P; Rao X; Wang J; Kowalski LP; Pickering CR; Dias-Neto E; Myers JN
Cancer; 2020 Oct; 126(20):4498-4510. PubMed ID: 32797678
[TBL] [Abstract][Full Text] [Related]
43. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma.
Sisk EA; Soltys SG; Zhu S; Fisher SG; Carey TE; Bradford CR
Head Neck; 2002 Sep; 24(9):841-9. PubMed ID: 12211048
[TBL] [Abstract][Full Text] [Related]
44. Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status.
Zhu X; Jamshed S; Zou J; Azar A; Meng X; Bathini V; Dresser K; Strock C; Yalamarti B; Yang M; Tomaszewicz K; Tjionas G; Mochel MC; Hutchinson L; Bledsoe JR
Mod Pathol; 2021 May; 34(5):1017-1030. PubMed ID: 33483624
[TBL] [Abstract][Full Text] [Related]
45. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
[TBL] [Abstract][Full Text] [Related]
46. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
[TBL] [Abstract][Full Text] [Related]
47. Cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal cancer.
Güran S; Pak I
Cancer Genet Cytogenet; 1999 Mar; 109(2):108-13. PubMed ID: 10087941
[TBL] [Abstract][Full Text] [Related]
48. TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients.
Braakhuis BJ; Rietbergen MM; Buijze M; Snijders PJ; Bloemena E; Brakenhoff RH; Leemans CR
Oral Dis; 2014 Sep; 20(6):602-8. PubMed ID: 24112103
[TBL] [Abstract][Full Text] [Related]
49. Human papillomavirus in early laryngeal carcinoma.
Baumann JL; Cohen S; Evjen AN; Law JH; Vadivelu S; Attia A; Schindler JS; Chung CH; Wirth PS; Meijer CJ; Snijders PJ; Yarbrough WG; Slebos RJ
Laryngoscope; 2009 Aug; 119(8):1531-7. PubMed ID: 19489068
[TBL] [Abstract][Full Text] [Related]
50. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
51. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
[TBL] [Abstract][Full Text] [Related]
52. Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
Helland A; Karlsen F; Due EU; Holm R; Kristensen G; Børresen-Dale Al
Br J Cancer; 1998 Jul; 78(1):69-72. PubMed ID: 9662253
[TBL] [Abstract][Full Text] [Related]
53. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
54. Locally advanced hypopharyngeal and laryngeal cancer: Influence of HPV status.
Bates JE; Morris CG; Hitchcock KE; Dziegielewski PT; Mendenhall WM; Amdur RJ
Radiother Oncol; 2019 Nov; 140():6-9. PubMed ID: 31174105
[TBL] [Abstract][Full Text] [Related]
55. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
56. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.
Dongre HN; Elnour R; Tornaas S; Fromreide S; Thomsen LCV; Kolseth IBM; Nginamau ES; Johannessen AC; Vintermyr OK; Costea DE; Bjørge L
Acta Obstet Gynecol Scand; 2024 Jan; 103(1):165-175. PubMed ID: 37840151
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance of cell cycle-associated proteins p16, pRB, cyclin D1 and p53 in resected oropharyngeal carcinoma.
Plath M; Broglie MA; Förbs D; Stoeckli SJ; Jochum W
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):53. PubMed ID: 30189895
[TBL] [Abstract][Full Text] [Related]
58. High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.
Kortekaas KE; Santegoets SJ; Abdulrahman Z; van Ham VJ; van der Tol M; Ehsan I; van Doorn HC; Bosse T; van Poelgeest MIE; van der Burg SH
J Immunother Cancer; 2019 Sep; 7(1):236. PubMed ID: 31481117
[TBL] [Abstract][Full Text] [Related]
59. [Prognostic and predictive value of koilocytosis, expression of e6 hpv types 16/18, p16ink4a, p53 in locally advanced squamous cell carcinomas of oral cavity and oropharynx, associated with human papillomavirus].
Riaboshapka AN
Georgian Med News; 2014 Nov; (236):48-55. PubMed ID: 25541826
[TBL] [Abstract][Full Text] [Related]
60. Clinical and molecular prognostic factors in operable laryngeal cancer.
Vlachtsis K; Nikolaou A; Markou K; Fountzilas G; Daniilidis I
Eur Arch Otorhinolaryngol; 2005 Nov; 262(11):890-8. PubMed ID: 15739081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
